Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors: Radioimmunotherapy with yttrium-90- ibritumomab tiuxetan in follicular non Hodgkin's lymphoma

NuklearMedizin

Volumn 50, Issue 1, 2011, Pages 39-47

  Grgic, Aleksandar ^a   Nestle, U ^a,b   Scheidhauer, K ^c   Puskas, C ^d   Ballek, E ^a   Hohloch, K ^e   Schubert, J ^a   Konig J ^f   Pinkert, J ^g   Truemper, L ^e   Hellwig, D ^a   Kirsch, C M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g BAYER AG   (Germany)

Author keywords

18F FDG PET; 90Y ibritumomab tiuxetan; Follicular lymphoma; Predictive factors; Radioimmunotherapy

Indexed keywords

IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN YTTRIUM Y 90; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INTERNET; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79952074184     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0322-10-06     Document Type: Article

References (40)

1. Alexander DD, Mink PJ, Adami HO et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007: 1-39. (Pubitemid 46732571)
2. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009; 50 (Suppl 1): 11S-20S.
3. Buske C, Gisselbrecht C, Gribben J et al. Refining the treatment of follicular lymphoma. Leuk Lymphoma 2008; 49 (Suppl 1): 18-26.
4. 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 494-504.
5. Cheson B. The case against heavy PETing. J Clin Oncol 2009; 27: 1742-1743.
6. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
7. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
8. Elstrom R, Guan L, Baker G et al. Utility of FDGPET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.
9. Fischer M, Grunwald F, Knapp WH et al. Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma. Nuklearmedizin 2009; 48: 215-220.
10. Foster T, Miller JD, Boye ME, Russell MW. Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconomics 2009; 27: 657-679.
11. Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-1208.
12. 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer. Am J Clin Oncol 2008; 31: 439-445.
13. Grgic A, Nestle U, Schaefer-Schuler A et al. FDGPET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning - an intraindividual comparison. Int J Radiat Oncol Biol Phys 2009; 73: 103-111.
14. Hiddemann W, Buske C, Dreyling M et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005; 23: 6394-6399. (Pubitemid 46222239)
15. Hohloch K, Zinzani PL, Linkesch W Jr et al. Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network. ASH Annual Meeting Abstracts 2008; 112: 3064.
16. Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol 2000; 11 (Suppl 1): 23-27.
17. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009; 50: 8-17.
18. 18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008; 8: 287-293.
19. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578. (Pubitemid 350002965)
20. Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449. (Pubitemid 40175970)
21. Karam M, Novak L, Cyriac J et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107: 175-183. (Pubitemid 43939045)
22. Kessler RM, Ellis JR Jr, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984; 8: 514-522. (Pubitemid 14122897)
23. Krak NC, Boellaard R, Hoekstra OS et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005; 32: 294-301. (Pubitemid 40562120)
24. Krause BJ, Beyer T, Bockisch A et al. FDG-PET/CT in oncology. German Guideline. Nuklearmedizin 2007; 46: 291-301. (Pubitemid 350301886)
25. 90Y: multicentric study. Ann Oncol 2010; 21: 1877-1883.
26. Schwartz LH, Mazumdar M, Brown W et al. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res 2003; 9: 4318-4323. (Pubitemid 37248386)
27. Seam P, Juweid ME, Cheson BD. The role of FDGPET scans in patients with lymphoma. Blood 2007; 110: 3507-3516. (Pubitemid 350159614)
28. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265. (Pubitemid 39166497)
29. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945. (Pubitemid 46909922)
30. Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy - initial experience. Radiology 2008; 246: 895-902.
31. 18F]fluoro-D-glucose uptake in normal tissues. Mol Imaging Biol 2007; 9: 83-90.
32. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51: 25-30.
33. 90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185-188.
34. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269. (Pubitemid 34831524)
35. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463. (Pubitemid 34525730)
36. Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804-1810. (Pubitemid 46668544)
37. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non- Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
38. 18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780-784.
39. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
40. Zinzani PL, Musuraca G, Alinari L et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007; 7: 291-295. (Pubitemid 46408194)